Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?

Autores de CIPF

• 

  Carmen Espinós Armero

  Autor

Participantes ajenos a CIPF

• Ferenci P

Grupos de Investigación

• Laboratorio de Enfermedades Raras Neurodegenerativas

Abstract

The diagnosis of Wilson disease is not always easy. For many patients, a combination of tests reflecting disturbed copper metabolism may be needed. Testing for ATP7B variants has become part of the routine diagnostic approach. The methods of genetic testing include analysis of the 21 coding exons and intronic flanking sequences, in which exons with recurrent variants would be prioritised depending on the mutation frequency in the local population. If sequencing the entire ATP7B gene cannot identify 2 variants and the suspicion for Wilson disease is high, after reviewing the clinical data, WES (whole-exome sequencing) or WGS (whole-genome sequencing) could be applied. A workflow based on the type and number of ATP7B variants responsible for Wilson disease is proposed. Genetic testing is indicated for confirmation of diagnosis, family screening, and screening of newborns and infants and in unclear cases suspected of suffering from Wilson disease. However, genetic testing is not a routine screening test for Wilson disease. If no additional variants can be identified, it can be assumed that other hereditary disorders may mimic Wilson disease (congenital disorders of glycosylation, MEDNIK syndrome, idiopathic or primary copper toxicoses).

Keywords

• CDG, congenital disorders of glycosylation, Copper metabolism, DMR, differentially methylated regions, Genetic diseases, ICC, Indian childhood cirrhosis, ICT, idiopathic or primary copper toxicosis, MLPA, multiplex ligation-dependent probe amplification, NGS, next-generation sequencing, Next-generation sequencing, PFIC, progressive familial intrahepatic cholestasis, WES, whole-exome sequencing, WGS, whole-genome sequencing, Whole-exome sequencing, Whole-genome sequencing, Wilson disease